Clinical Trials Sponsored by Cytoki Pharma

Total 8374 results

UCB Pharma

Completed

Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome.

Fibromyalgia Syndrome

United States
UCB Pharma

Completed

A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis (SP906)

Migraine

United States
UCB Pharma

Completed

Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy

Epilepsy

United States, Czechia, Germany, Poland
LEO Pharma

Terminated

Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.

Alopecia Areata

Denmark
Patara Pharma

Completed

Treatment of Uremic Pruritus With PA101B

Uremic Pruritus

United States
Kukje Pharma

Completed

KJ-TFC-004 Drug-drug Interaction Study

Ocular Hypertension | Glaucoma | Eye Diseases

Korea, Republic of
Zealand Pharma

Completed

Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction

Focus of Study is STEMI

Denmark
LEO Pharma

Completed

An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With Calcipotriene/Betamethasone Dipropionate (Taclonex®) Topical Suspension, and Effect on Quality of Life

Psoriasis Vulgaris

United States
UCB Pharma

Completed

Assess Safety and Efficacy of Lacosamide in Patients With Partial Seizures

Epilepsy

France, Poland, United Kingdom, Germany, Spain, Finland, Australia, Russian Federation, Hungary, Lithuania, Sweden, Czechia, Croatia
LEO Pharma

Completed

Skin IaM: An Exploratory Clinical Trial to Evaluate Changes in Skin Appearance, Colour, and/or Texture Following the Induction of a Local Inflammatory Skin Response

Skin Inflammation

Australia
Vifor Pharma

Completed

Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Iron Deficiency and Chronic Heart Failure (EFFECT-HF)

Chronic Heart Failure | Iron Deficiency

Netherlands
LEO Pharma

Completed

Vasoconstriction Trial With LEO 90100 Aerosol Foam

Psoriasis Vulgaris

France
LEO Pharma

Completed

Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts

Anogenital Warts

Denmark
LEO Pharma

Completed

LEO 32731 - A Phase I Study in Healthy Subjects

Psoriasis Vulgaris

United Kingdom
Zealand Pharma

Completed

ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed Glucagon

Diabetes Mellitus Type 1

Germany
Innate Pharma

Terminated

Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity

Squamous Cell Carcinoma of the Oral Cavity

Germany, Spain
Patara Pharma

Completed

Treatment of Indolent Systemic Mastocytosis With PA101

Systemic Mastocytosis | Mastocytosis | Indolent Systemic Mastocytosis

France, Germany, Spain, Italy, Netherlands
LEO Pharma

Completed

Effect of LEO 90100 on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis VulgarisExtensive Psoriasis Vulgaris

Psoriasis Vulgaris

Canada
LEO Pharma

Completed

LP0058-1005 - A Open-Label, Four-Way Crossover and Food-Effect Study of LEO 32731 in Healthy Subjects

Psoriasis Vulgaris

United Kingdom
LEO Pharma

Completed

Skin Irritation Test of LEO 80185 Gel in Healthy Japanese Subjects

Skin and Connective Tissue Diseases

Japan
UCB Pharma

Completed

Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects

Systemic Lupus Erythematosus

Japan
PLx Pharma

Completed

Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients (RITE)

Diabetes Mellitus, Type 2

United States
Advanz Pharma

Completed

A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation (MK-6621-010 AM4)

Atrial Fibrillation
Zealand Pharma

Completed

Multiple Ascending Doses of ZP4207 Administered to HV to Evaluate the Safety, Tolerability, PKs and PDs of ZP4207

Hypoglycemia

Germany
LEO Pharma

Completed

Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis

Scalp Psoriasis

United States
AM-Pharma

Withdrawn

Safety of hLF1-11 for the Treatment of Infectious Complications Among HSCT Recipients

Fungal Infection | Bacterial Infection

Netherlands
UCB Pharma

Completed

The Use of Rotigotine for Treatment of Reducing Signs and Symptoms of Fibromyalgia in Adults. (SP888)

Fibromyalgia Syndrome

United States
LEO Pharma

Completed

The Pharmacokinetics of LEO 90105 (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Extensive Psoriasis Vulgaris

Psoriasis Vulgaris

Japan
Sigmoid Pharma

Completed

PK, Safety & Tolerability of CyCol® Versus Sandimmune® in Healthy Subjects (CYC102)

Healthy
LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris

Psoriasis Vulgaris

Canada
UCB Pharma

Completed

A Study of Brivaracetam in Subjects With Partial Onset Seizures

Epilepsy, Focal

France, Poland, United Kingdom, Belgium, Germany, Spain, Czech Republic, Finland, Netherlands
LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Plus Betamethasone Gel in the Treatment of Scalp Psoriasis

Psoriasis of Scalp

Canada, Denmark, France, Norway, Portugal, Spain, Sweden, United Kingdom
LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Cream and (Calcipotriol + Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris

Psoriasis Vulgaris

Belgium, Canada, France, Germany, Netherlands, Spain, United Kingdom
LEO Pharma

Completed

Efficacy of Calcipotriol Plus Betamethasone Gel Versus Calcipotriol Scalp Solution in Scalp Psoriasis

Psoriasis of Scalp

France, Canada, Belgium, Denmark, Sweden
LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Psoriasis Vulgaris

Psoriasis Vulgaris

Ireland, Germany, United Kingdom, Canada, Sweden
LEO Pharma

Completed

Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis

Psoriasis

United States
UCB Pharma

Completed

Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin (PAL)

Allergic Rhinitis | Chronic Urticaria

United States
Innate Pharma

Completed

Safety and Tolerability of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

Germany
UCB Pharma

Completed

Observational Study in Infants Who Are Prescribed Treatment With Keppra® (Levetiracetam) Oral Solution

Epilepsy

France, Germany, Greece, Italy, Poland, Spain, United Kingdom
UCB Pharma

Completed

Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder

Generalized Anxiety Disorder | Panic Disorder

United States
UCB Pharma

Completed

Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch

Parkinson's Disease

United States, Chile, Mexico, India, Peru
UCB Pharma

Terminated

Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease

Parkinson's Disease

Spain, South Africa, New Zealand, Hungary, United States, Germany, Italy, Australia, Finland, United Kingdom, Poland
UCB Pharma

Terminated

Alprostadil in Maculopathy Study (AIMS)

Macular Degeneration

Germany
UCB Pharma

Completed

Trial to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine in Healthy Korean Subjects

Parkinson's Disease

Korea, Republic of
UCB Pharma

Completed

A Trial to Investigate Safety and Efficacy of SPM927 in Painful Diabetic Neuropathy

Painful Diabetic Neuropathy
UCB Pharma

Completed

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease

Early Stage Parkinson's Disease

Poland, United Kingdom, Germany, Spain, Switzerland, Belgium, South Africa, New Zealand, Czech Republic, Austria, Hungary, Australia, Italy, Israel, Sweden, Norway, Croatia, Netherlands, Finland, France
UCB Pharma

Completed

An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease

Idiopathic Parkinson's Disease

United States, Germany, Spain, Austria, Israel, Italy, South Africa, United Kingdom
UCB Pharma

Completed

A Trial to Compare the Efficacy of Rotigotine Transdermal Patch to That of Ropinirole on Early Morning Motor Impairment and Sleep Disorders in Subjects With Early-Stage, Idiopathic Parkinson's Disease

Parkinson's Disease

Germany
UCB Pharma

Completed

An Extension Trial to Investigate Long-Term Treatment With Transdermal Rotigotine in Idiopathic Restless Legs Syndrome

Restless Legs Syndrome

United States
UCB Pharma

Completed

An Open-Label Follow-on Trial to Assess the Long-Term Safety and Efficacy of Oral SPM 927 in Subjects With Postherpetic Neuralgia (PHN)

Postherpetic Neuralgia

Germany

3

Subscribe